These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35843739)

  • 21. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
    Basu B; Krebs MG; Sundar R; Wilson RH; Spicer J; Jones R; Brada M; Talbot DC; Steele N; Ingles Garces AH; Brugger W; Harrington EA; Evans J; Hall E; Tovey H; de Oliveira FM; Carreira S; Swales K; Ruddle R; Raynaud FI; Purchase B; Dawes JC; Parmar M; Turner AJ; Tunariu N; Banerjee S; de Bono JS; Banerji U
    Ann Oncol; 2018 Sep; 29(9):1918-1925. PubMed ID: 30016392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
    Gonzalez-Angulo AM; Akcakanat A; Liu S; Green MC; Murray JL; Chen H; Palla SL; Koenig KB; Brewster AM; Valero V; Ibrahim NK; Moulder-Thompson S; Litton JK; Tarco E; Moore J; Flores P; Crawford D; Dryden MJ; Symmans WF; Sahin A; Giordano SH; Pusztai L; Do KA; Mills GB; Hortobagyi GN; Meric-Bernstam F
    Ann Oncol; 2014 Jun; 25(6):1122-7. PubMed ID: 24669015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
    Gonzalez-Angulo AM; Krop I; Akcakanat A; Chen H; Liu S; Li Y; Culotta KS; Tarco E; Piha-Paul S; Moulder-Thompson S; Velez-Bravo V; Sahin AA; Doyle LA; Do KA; Winer EP; Mills GB; Kurzrock R; Meric-Bernstam F
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25688104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
    Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
    Abu-Khalaf MM; Baumgart MA; Gettinger SN; Doddamane I; Tuck DP; Hou S; Chen N; Sullivan C; Lezon-Geyda K; Zelterman D; Hatzis C; Deshpande H; Digiovanna MP; Azodi M; Schwartz PE; Harris LN
    Cancer; 2015 Jun; 121(11):1817-26. PubMed ID: 25649370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
    Hernández-Prat A; Rodriguez-Vida A; Juanpere-Rodero N; Arpi O; Menéndez S; Soria-Jiménez L; Martínez A; Iarchouk N; Rojo F; Albanell J; Brake R; Rovira A; Bellmunt J
    Mol Cancer Res; 2019 Sep; 17(9):1931-1944. PubMed ID: 31160383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
    Heudel P; Frenel JS; Dalban C; Bazan F; Joly F; Arnaud A; Abdeddaim C; Chevalier-Place A; Augereau P; Pautier P; Chakiba C; You B; Lancry-Lecomte L; Garin G; Marcel V; Diaz JJ; Treilleux I; Pérol D; Fabbro M; Ray-Coquard I
    JAMA Oncol; 2022 Jul; 8(7):1001-1009. PubMed ID: 35551299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
    Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
    Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
    Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
    Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
    Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
    Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
    Juric D; de Bono JS; LoRusso PM; Nemunaitis J; Heath EI; Kwak EL; Macarulla Mercadé T; Geuna E; Jose de Miguel-Luken M; Patel C; Kuida K; Sankoh S; Westin EH; Zohren F; Shou Y; Tabernero J
    Clin Cancer Res; 2017 Sep; 23(17):5015-5023. PubMed ID: 28490463
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
    Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
    Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.